Real‐World Outcomes of Hypomethylating Agents for Higher‐Risk Myelodysplastic Syndromes: Report From the Nationwide Multicenter Thai MDS Study
Theerin Lanamtieng, Chantana Polprasert, Pimjai Niparuck, Phatsorn Choksomnuk, Thanawat Rattanathammethee, Wasithep Limvorapitak, Kannadit Prayongratana, Rattapan Lamool, Archrob Khuhapinant, Weerapat Owattanapanich, Pisa Phiphitaporn, Kanchana Chansung, Suporn Chuncharunee, Kalyani Sen · 2026
Read Real‐World Outcomes of Hypomethylating Agents for Higher‐Risk Myelodysplastic Syndromes: Report From the Nationwide Multicenter Thai MDS Study by Theerin Lanamtieng, Chantana Polprasert, Pimjai Niparuck, Phatsorn Choksomnuk, Thanawat Rattanathammethee, Wasithep Limvorapitak, Kannadit Prayongratana, Rattapan Lamool, Archrob Khuhapinant, Weerapat Owattanapanich, Pisa Phiphitaporn, Kanchana Chansung, Suporn Chuncharunee, Kalyani Sen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13575782.txt.
Description
Hypomethylating agents are the standard treatment for higher-risk myelodysplastic syndromes, blood cancers of older adults, but access is uneven worldwide. The authors use Thailand's national MDS registry to compare these drugs with best available treatment in 155 newly diagnosed patients, followed for a median of three years. About 55 percent receive the standard fallback care and 45 percent the hypomethylating drugs. Patients who had stem cell transplants are excluded to keep the comparison clean.
Survival clearly favors the drug group: a median of 15 months against 6. Adjusted analysis cuts the risk of death by about 42 percent for those on the agents. Older age and the highest risk scores predict worse outcomes in both groups. The authors present this as real-world proof, outside the trial setting, that these drugs extend life in Thai practice. They argue the gap in access deserves policy attention.
Catalog record
| CREATOR | Theerin Lanamtieng, Chantana Polprasert, Pimjai Niparuck, Phatsorn Choksomnuk, Thanawat Rattanathammethee, Wasithep Limvorapitak, Kannadit Prayongratana, Rattapan Lamool, Archrob Khuhapinant, Weerapat Owattanapanich, Pisa Phiphitaporn, Kanchana Chansung, Suporn Chuncharunee, Kalyani Sen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |